{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:45:17Z","timestamp":1790801117516,"version":"4.1.0"},"reference-count":11,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>The primary outcome of this study was to describe the dosing regimen of tadalafil in neonates and infants diagnosed with pulmonary hypertension (PH) secondary to bronchopulmonary dysplasia (BPD). Secondary outcomes included tolerability, efficacy, adverse events, discontinuation of therapy, and changes in echocardiography.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This was a single-center, retrospective review of neonates and infants &amp;lt;1 year of age at initiation of tadalafil for PH secondary to BPD from January 2010 to November 2021. Data collected from the electronic medical record included patient demographics, tadalafil dosing, oxygen support, mechanical ventilation, concomitant PH medications, adverse events, and echocardiography information.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Forty-two patients\u20144 neonates and 38 infants\u2014met the inclusion criteria. The postnatal and post-menstrual age (median, IQR) at diagnosis were 121 (35.5\u2013153.5) days and 42.6 (40.6\u201347.6) weeks, respectively. The initial and highest tadalafil doses (median, range) were 1 (0.25\u20132) and 1 (0.5\u20132) mg\/kg\/day. Only 1 patient experienced pulmonary overcirculation and required tadalafil to be discontinued. Over half (57.1%) of the patients in this study discontinued tadalafil therapy owing to improvements in pulmonary artery pressures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Tadalafil 1 mg\/kg\/day was the most commonly used dose regimen in neonates and infants. Tadalafil at this dose of 1 mg\/kg\/day appears well tolerated in neonates and infants with PH secondary to BPD and correlates with improvements in pulmonary artery pressures. Further studies evaluating tadalafil in comparison to other phosphodiesterase-5 inhibitors in neonates with PH secondary to BPD are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.2.140","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T17:22:26Z","timestamp":1712596946000},"page":"140-143","source":"Crossref","is-referenced-by-count":3,"title":["Tadalafil in Neonates and Infants With Pulmonary Hypertension Secondary to Bronchopulmonary Dysplasia"],"prefix":"10.5863","volume":"29","author":[{"given":"Amy","family":"Kiskaddon","sequence":"first","affiliation":[{"name":"Department of Pharmacy (AK), Johns Hopkins All Children\u2019s Hospital, St. Petersburg, FL;"},{"name":"Department of Pediatrics, Division of Cardiology (AK), Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaka","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (TD), Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Mauriello","sequence":"additional","affiliation":[{"name":"Division of Pediatric Cardiology (DM), Johns Hopkins All Children\u2019s Hospital, St. Petersburg, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"3","key":"2024040817222016700_i2331-348X-29-2-140-b01","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41390-020-0993-4","article-title":"Pulmonary hypertension in bronchopulmonary dysplasia","volume":"89","author":"Hansmann","year":"2021","journal-title":"Pediatr Res"},{"issue":"6","key":"2024040817222016700_i2331-348X-29-2-140-b02","doi-asserted-by":"crossref","first-page":"e2114140","DOI":"10.1001\/jamanetworkopen.2021.14140","article-title":"Rates of bronchopulmonary dysplasia following implementation of a novel prevention bundle","volume":"4","author":"Villosis","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2024040817222016700_i2331-348X-29-2-140-b03","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/17512433.2020.1850257","article-title":"Oral drugs used to treat persistent pulmonary hypertension of the newborn","volume":"13","author":"Zhang","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"2024040817222016700_i2331-348X-29-2-140-b04","doi-asserted-by":"crossref","first-page":"e20161450","DOI":"10.1542\/peds.2016-1450","article-title":"Pulmonary hypertension therapy and a systematic review of efficacy and safety of PDE-5 inhibitors","volume":"139","author":"Unegbu","year":"2017","journal-title":"Pediatrics"},{"key":"2024040817222016700_i2331-348X-29-2-140-b05","author":"Tadalafil [package insert]","year":"2021"},{"issue":"7","key":"2024040817222016700_i2331-348X-29-2-140-b06","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2146\/ajhp110034","article-title":"Stability of an extemporaneously prepared tadalafil suspension","volume":"69","author":"Pettit","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"2024040817222016700_i2331-348X-29-2-140-b07","first-page":"7","article-title":"Oral tadalafil in children with pulmonary arterial hypertension","volume":"66","author":"Shiva","year":"2016","journal-title":"Drug Res (Stuttg)"},{"issue":"5","key":"2024040817222016700_i2331-348X-29-2-140-b08","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/03007995.2017.1297931","article-title":"Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data","volume":"33","author":"Yamazaki","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2024040817222016700_i2331-348X-29-2-140-b09","doi-asserted-by":"crossref","first-page":"20458940211024955","DOI":"10.1177\/20458940211024955","article-title":"Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo controlled study","volume":"11","author":"Ivy","year":"2021","journal-title":"Pulm Circ"},{"issue":"1","key":"2024040817222016700_i2331-348X-29-2-140-b10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ppul.22797","article-title":"Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes","volume":"49","author":"del Cerro","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"2024040817222016700_i2331-348X-29-2-140-b11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1515\/jpm-2021-0366","article-title":"Pulmonary hypertension in infants with bronchopulmonary dysplasia: risk factors, mortality and duration of hospitalisation","volume":"50","author":"Arattu Thodika","year":"2021","journal-title":"J Perinat Med"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/2\/140\/3354469\/i2331-348x-29-2-140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/2\/140\/3354469\/i2331-348x-29-2-140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:24Z","timestamp":1738780884000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/2\/article-p140.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,8]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.2.140","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}